This activity is supported by educational grants from AstraZeneca, Clovis Oncology, Lilly, and Merck & Co.
Management of Patients With Cytotoxic Chemotherapy
Beth Eaby-Sandy, MSN, CRNP, OCN®
University of Pennsylvania
This activity will provide advanced practitioners with valuable insights into cytotoxic chemotherapy treatment strategies for patients with non–small cell lung cancer of both squamous and non-squamous histology. Discussions include first-line treatment options, treatment considerations in the elderly patient, maintenance chemotherapy, second-line therapy, and more.
Use of Diagnostic Tests in Advanced Non–Small Cell Lung Cancer: Skills Presentation
Targeted Therapies in Advanced Non–Small Cell Lung Cancer
Management of Patients Treated With Immunotherapy
Navigating the Landscape of Molecular Testing and Treatments With Targeted Therapies for Patients With Non-Small Cell Lung Cancer
What is the role of EGFR mutations in patients with NSCLC?
What is T790m and describe its role in drug resistance?
What is ALK and how does it impact the treatment of NSCLC?
What should advanced practitioners know about the side effect profiles of targeted treatments for NSCLC?
What should pharmacists know about combining treatment agents for patients with NSCLC?
Bone Marrow Biopsy Demonstration Video